HIGHLIGHTS
Revenue reached
Growth continues to be driven by patient uptake due to the efficacy and reliability of the products in the portfolio, product launches in new markets and the continued resilience of mature brands.
Strategic brand performance:
·
· Revenue of Abilify Maintena[®] increased 19% to
· Revenue of Brintellix[®]/Trintellix[®] increased 14% to
· Revenue of Northera[®] increased 16% to
· Revenue of Rexulti[®]/Rxulti[®] increased 24% to
· Revenue of Vyepti reached
Market performance:
·
· Revenue in
· Revenue in International Markets increased 8% to
· Revenue in
In connection with the financial report, Lundbeck's President and CEO
"I am very pleased with the results for the first nine months of this unprecedented year. Our brands have demonstrated impressive resilience, continuing to perform well across all markets and delivering solid growth. Patient feedback on the effectiveness of Vyepti is strongly positive and the results of the RELIEF study confirmed the powerful and fast onset profile of the drug, supporting our long-term growth expectations for the brand. Our solid brand performance combined with our strong financial position puts us on robust footing for the future."
DKK million 9M 2020 9M 2019 Growth
Core Revenue* 13,397 12,615 6%
Core EBIT* 3,714 4,010 (7%)
Core EPS* 14.87 15.40 (3%)
Core EBIT margin* 27.7% 31.8% -
Reported Revenue 13,397 12,615 6%
Reported EBIT 1,786 3,317 (46%)
Reported EPS 6.06 12.27 (51%)
Reported EBIT margin 13.3% 26.3% -
For definition of the measures "Core Revenue", "Core EBIT", "Core EBIT margin" and "Core EPS", see note 6 Core reporting
Revenue of the five strategic brands combined grew by 19% (19% in local currencies), thereby reaching
Core EBIT reached
The free cash flow increased from
The financial guidance range has been narrowed. Lundbeck now expects revenue to reach
Ottiliavej 9, 2500 Valby,
+45 3630 1311
info@lundbeck.com
https://news.cision.com/h--lundbeck-a-s/r/solid-performance-across-strategic-brands-with-19--growth-in-the-first-nine-months-of-2020--financia,c3230185
https://mb.cision.com/Main/18215/3230185/1329663.pdf
(c) 2020 Cision. All rights reserved., source